Who they are

The company employs 14,000 people worldwide in more than 50 countries, and has nearly 600 employees in the UK, more than half of whom work in research. It is now part of Schering-Plough.


Organon’s business headquarters in the UK are in Cambridge. From there experts in sales, marketing, administration and a variety of professional disciplines handle the company’s commercial operations throughout the country.


Organon’s drug discovery research complex at Newhouse, Scotland, is one of the largest of its kind in the country. More

What they make

Products that contribute to the health of people and their quality of life. Innovative prescription medicines for gynaecology, mental health, anaesthesia and cardiovascular disease.

Where they make them in Scotland

Organon Research Scotland,





Tel: 01698 736000

What they want

“Organon operates within a highly competitive global environment. Our success is based on recruiting and retaining highly talented, committed and competent people. Career opportunities can be both local and global. Organon provides an extensive portfolio of training and development opportunities.” More


“Creativity, perseverance, managerial skills, career potential, and multidisciplinary team spirit feature just as prominently among Organon's recruitment criteria as educational background.” More


What it’s like to work there

“Trust and integrity are extremely important to us and as a result we focus on identifying these values throughout the recruitment process. I have been with the company for over 5 years. It is highly motivating to work for an organisation where the culture is increasingly open and fun (albeit hard work!).” More


Phil Jones, a medicinal chemist from Manchester chose to move three years ago to Organon in Newhouse, in the heart of Scotland’s central belt.


Andy Edwards had always been interested in chemistry since school. Joining Organon’s research facility in Newhouse, just outside Glasgow, dropped him on the doorstep of the great outdoors.

Google Earth

Medium resolution image.


  • U.S. Food and Drug Administration assigns priority review status to sugammadex - a new drug that “has the potential to change the way doctors practice anaesthesia”.
  • Schering-Plough will acquire Organon BioSciences for approximately Euro 11 billion in cash, or about $14.4 billion.